James Barlow is a member of the Board of Directors of NAHS Holding, Inc., an Employee Stock Ownership Plan company, whose affiliates provide post-acute care, subacute care, short and long-term rehabilitation, and skilled nursing in the United States. Mr. Barlow is a C-level financial executive with more than 30 years of experience leading teams in the successful strategic achievement of financial and operational goals, and expertise in domestic and international operations, financial planning, forecasting and reporting, restructurings, business development and integrations, treasury and investor relations. As an Executive Officer (Principal Accounting Officer) at Allergan, Inc. from January 2002 to March 2015, he oversaw financial due diligence, integration and structuring for all significant asset purchases, sales, business combinations and licensing transactions, the spin-off of Advanced Medical Optics, the $3.3 billion acquisition of Inamed Corporation and more than $4.5 billion in other transactions. He ensured consistent application of corporate policies and procedures and alignment with global reporting and corporate compliance requirements, made recommendations globally to improve financial operations and participated in robust financial planning/forecasting activities. Prior to joining Allergan, Mr. Barlow served as Chief Financial Officer of Wynn Oil Company, a division of Parker Hannifin Corporation, during 2001, Treasurer and Controller of Wynn’s International, Inc. from 1990 to 2000 and Vice President and Controller of Ford Equipment Leasing Company from 1986 to 1990. From 1983 to 1985 Mr. Barlow worked for the accounting firm Deloitte Haskins and Sells. Mr. Barlow received a Bachelor of Science degree in Accounting, graduating magna cum laude, from Brigham Young University and a Master of Accountancy, graduating with honors - high distinction, from Brigham Young University. He is a certified public accountant (inactive).
Dina Berdieva, Vice President, Clinical OperationsBio
Prior to joining Arcturus Therapeutics, Dina was one of the founding members of the Gates Medical Research Institute, serving as the Head of Project Management & Clinical Operations. Dina has 20 years of industry experience which spans small biotechnology, global pharmaceutical, and contract research organizations. Much of her career has been focused on the development of vaccines and treatments for infectious diseases. Dina holds a Bachelor of Arts degree from Clark University and a Master of Public Health degree from Boston University with a dual concentration in International Health Epidemiology and Biostatistics.
Natasha Bowman, Vice President, Head of Human ResourcesBio
Natasha O. Bowman, has more than 25 years of in the field of Human Resources with robust industry and leadership experience in the pharmaceutical, medical device, manufacturing and public sectors. Ms. Bowman most recently was the Senior Vice President of Human Resources at Synthetic Genomics for over 7 years where she served as a strategic adviser providing guidance on all HR related matters to the CEO, Board of Directors, and other members of the executive team. She previously held positions in start-up, mid-size, and Fortune 500 companies including Althea Technologies, ACADIA Pharmaceuticals and Pfizer Inc. where she played a key role in the start-up, growth, and mergers & acquisitions of those organizations. Ms. Bowman received a B.S in Business Management from San Diego State University. She was named as one of San Diego’s 500 Most Influential Business Leaders by the San Diego Business Journal in 2018, 2019, and 2020. She is on the Board of Directors for the non-profit organizations San Diego Girl Scouts, San Diego HR Forum, Lakeside River Park Conservancy, and Friends of Music.
Juthamart Brady, Research Associate, Drug Discovery
Giulio Cattarossi, Senior Research Associate, RNA Sciences
Lena Ceballos, Public Relations & Marketing Specialist
Emily Chao, Research Associate I, Frontier Science
Pad Chivukula, Ph.D., is the Chief Scientific Officer and Chief Operating Officer of Arcturus Therapeutics. Dr. Chivukula has an exceptional and technically solid foundation in nanoparticle technology. Prior to Arcturus, from 2008 until February 2013, Dr. Chivukula was employed by Nitto, where his titles included Group Leader and Chief Scientist. Dr. Chivukula brings over 15 years of experience in drug delivery and therapeutic drug development, including leading the polymeric RNAi research department at Nitto. Dr. Chivukula has a Ph.D. in Pharmaceutical Chemistry from the University of Utah where he specialized in nanoparticle technology.
Brenda Clemente, Manager, Formulation & Process Development
Diana Correa, Research Assistant, Analytical Development
Alex Daily, Purchasing Manager
Michael Davis, Research Assistant, Formulation Development
ThanhChau Dam, Sr. Research Associate, Translational Biology
Michael Delbuono, Research Associate I, Analytical Development
Yisong Deng, Scientist I, Analytical Development
Nadja El-Mecharrafie, Research Associate II, Frontier Science
Dr. Peter Farrell is the founder, former long-term CEO and current Chairman of ResMed (NYSE:RMD). Farrell has been Chairman and a director of ResMed since 1989, when the company began as a management buyout of sleep technology from Baxter Healthcare. Peter was previously Foundation Director of the University of New South Wales (UNSW) Graduate School for Biomedical Engineering (1978-89) while simultaneously serving as Vice President of Research & Development for Baxter Healthcare in Tokyo (1984-89). He is also on the board of trustees of The Scripps Research Institute in La Jolla and is Chairman of the Boston-based POC NMR diagnostic company, WaveGuide. Dr. Farrell is a fellow or honorary fellow of several professional bodies, including the US National Academy of Engineering. He was inducted as 1998 San Diego Entrepreneur of the Year for Health Sciences, 2001 Australian Entrepreneur of the Year and 2005 US National Entrepreneur of the Year for Health Sciences. In 1998, Peter joined the Sleep Medicine Executive Council at Harvard Medical School, served as vice chairman from 2000 to 2010 and then as chairman from 2010 until 2013. He is on various academic advisory boards including UCSD's Jacobs School of Engineering, where he was named the 2012 Gordon Fellow, UCSD's Rady Business School and the MIT Dean of Engineering's Advisory Council. Peter holds a B.E. with honors in chemical engineering from the University of Sydney, an SM in chemical engineering from MIT, a PhD in bioengineering from the University of Washington, Seattle, and a DSc from UNSW for research which resulted in improved treatment for both hemodialysis and peritoneal dialysis patients.
Adam Finochio, Research Assistant, Formulation Development
David Geller, Vice President, Clinical Development for Pulmonary and Rare DiseasesBio
, Vice President, Clinical Development for Pulmonary and Rare Diseases
David Geller is a pediatric pulmonologist with more than 30 years of clinical research experience in academic and industry settings. Prior to joining Arcturus Therapeutics, David spent 6 years at AbbVie where he led a cross-functional Clinical Strategy Team and Phase I-II studies for development of a combination CFTR-modulator therapy involving three novel compounds. Prior to that he conducted monoclonal antibody trials in cystic fibrosis (CF) and asthma at KaloBios. In academia David was Associate Clinical Professor at Florida State University School of Medicine and the University of Central Florida School of Medicine. David was responsible for the conduct of Phase I - IV trials in CF, asthma, and other respiratory disorders for numerous inhaled therapies, CFTR modulators, and biologics. He founded an academic aerosol research lab to study and improve drug-delivery efficiency to lungs and assist pharmaceutical/biotech sponsors to optimize delivery of their therapies with the appropriate delivery devices, and ultimately reduce time burden for patients. While in academia David also consulted for numerous pharma, biotech, and device companies on issues including aerosol delivery, protocol design, enrollment strategies, and messaging for marketing and education. David is dedicated to making a positive impact on the health of children and adults with cystic fibrosis (CF) and other rare, life-shortening diseases, and he has strong ties with the Cystic Fibrosis community including global CF Foundations and Societies, thought leaders and clinicians.
Kyra Gillard, Research Associate I, Formulation Development
Abraham Gomez, Senior Research Associate, Translational Biology
Michael R. Hodges, M.D., BSc. is an infectious disease clinician and RNA medicines drug development executive with 30 years of experience within the biopharmaceutical industry. He is currently Chief Medical Officer (CMO) at Amplyx Pharmaceuticals, developing drug treatments for life-threatening viral and fungal infections in immunocompromised patients. Prior to Amplyx he was the CMO for two RNA platform companies, Santaris A/S and Altair Therapeutics Inc., developing drugs for infectious diseases, cancer, metabolic and respiratory diseases. Previously, he served in Pfizer Global Research and Development where he worked on multiple infectious diseases and oncology development programs. Dr. Hodges earned his M.D. (MBBS) and a BSc. In Pharmacology, from the University of London, UK.
Dr. Holmes is currently a Distinguished Professor of Medicine at the University of California, Vice Chancellor/Dean of Health Sciences Emeritus at the University of California, San Diego, and CEO/President of the Sanford Consortium for Regenerative Medicine. He became the Executive Deputy Chairman of the Biomedical Research Council and the Executive Chairman of the National Medical Research Council in Singapore in October 2006; he is currently a Senior Fellow in A*STAR and Advisor to the National Research Council of Singapore. He holds an appointment as the Lien Ying Chow Professor of Medicine at the Yong Loo Lin School of Medicine, National University of Singapore. For his contributions to the Singapore government, Dr. Holmes was made an Honorary Citizen in 2011, and he was awarded the President’s Science and Technology Medal in 2017. Dr. Holmes also served on the Council of Advisors for the National Institute for Diabetes, Digestive, and Kidney Diseases of the National Institutes of Health. He served as Chair of the Research Advisory Board of GlaxoSmithKline, the SAB of Ajinomoto and Board of Directors of Tularik, Inc. He also served on the Grand Challenges Explorations Innovation Review Panel for the Gates Foundation. He has been elected to membership in the American Society for Clinical Investigation, the Association of American Physicians, Fellow of the American Association for the Advancement of Science, and a member of the United States National Academy of Medicine.
Hyojung Hong, Research Associate I, Formulation Development
Dr. Hughes has over 20 years of experience building and leading clinical development and medical affairs teams at leading biopharma companies. He has been involved in more than 50 clinical trials with more than 25 drugs across multiple therapeutic areas including cardiovascular, metabolic, neurology, oncology, infectious diseases, rheumatology, ophthalmology and several rare diseases, in the U.S. and globally. Dr. Hughes has also played a key role in the submission of multiple NDA/MAA applications. Most recently he served as the Chief Medical Officer of Organovo where he led the non-clinical and clinical development teams developing bioprinted tissues for treatment of hepatic and renal diseases. Prior to that he was Chief Clinical Development Officer at Ionis Pharmaceuticals, where he led a team that managed the global clinical development of multiple drugs across several therapeutic areas. He has also held positions at Biogen Idec, CSL Behring and Sanofi. Dr. Hughes is Board Certified in Pharmaceutical Medicine and received his medical degree from Imperial College, London. He also has an MBA from Imperial College Business School.
Hannah Huynh, Laboratory Coordinator
Daniel Hwang, Accounting Supervisor
Priya Karmali, VP, Technology Innovation and DevelopmentBio
Priya Karmali is Vice President of Technology Innovation and Development at Arcturus Therapeutics. In her current position, she is responsible for research and development efforts for LUNAR® technology, Arcturus’ lipid mediated nucleic acid delivery system. Priya has over 20 years of experience in the field of lipid mediated nucleic acid delivery from discovery to development and has led drug product development of multiple RNA based therapeutics that are currently in various phases of clinical trials. Prior to Arcturus, Priya led formulation and drug product development of multiple miRNA candidates at Regulus Therapeutics. Prior to Regulus, Priya held positions of increasing responsibility at Nitto Denko where she led formulation development efforts for ND-L02-s0201, a Vitamin A targeted siRNA lipid nanoparticle, currently in various stages of clinical trials for hepatic and Idiopathic Pulmonary fibrosis. Priya received her PhD in Chemistry from the Indian Institute of Chemical Technology, India where her doctoral research was focused on development of novel liposomal nucleic acid delivery systems for use in non-viral gene therapy and DNA vaccination. She pursued her postdoctoral research at Sanford-Burnham-Preby’s-Medical Discovery Institute, La Jolla, CA focusing on developing targeted nanoparticles for drug delivery. Priya is an author and co-inventor on over 40 publications and patents.
Lisa Kieweg-Thompson, Research Associate II, RNA Production
Jae Heon (Jay) Kim, Research Associate I, Formulation Development
Michelle Kim, Research Associate I, Analytical Development
Mukunda Krishna, Senior Process Engineer II, Technical Transfer
Kristen Kuakini, Research Associate II
Greg Kubczak, Director, Technical Services and Manufacturing
K.C. Kummerfeld, CPA has over 20 years of financial executive experience working in fast paced companies within the Biotechnology and Technology industries. Prior to Arcturus, Mr. Kummerfeld worked in various Silicon Valley Technology Companies including Openwave Systems, Inc. where he held the role of Corporate Controller and helped establish the key accounting and finance controls necessary to grow the public company to over $400 million annual revenues and over 2,500 employees. Mr. Kummerfeld also worked for the accounting firm of KPMG after graduating from San Diego State University.
Lance Kurata has served as the Chief Legal Officer of Arcturus Therapeutics since August 2020. Prior to Arcturus, from 2006 to 2020, Mr. Kurata was a partner at Mintz Levin and Chair of the West Coast Technology Transactions Practice. From 2002 to 2006, he was a partner at Fish & Richardson, where he was a member of the corporate group and nationwide head of the technology transactions practice. From 1996 until 2002, Mr. Kurata practiced corporate law at Brobeck Phleger & Harrison, specializing in strategic collaborations, public and private financings, mergers and acquisitions and corporate governance. Mr. Kurata is licensed to practice law in the State of California. He received his Juris Doctor (JD) degree from Stanford Law School and was an editor of Stanford Law Review.
Robin Lee, Senior Research Associate, Analytical Development
Maral Llewellyn, Senior Scientist, Bioanalytical
Angel Leu, Senior Research Associate, Frontier Science
Pattraranee (Patty) Limphong, Associate Director, Drug Discovery
Kelly Lindert, Senior Vice President, Head of Vaccine Clinical DevelopmentBio
, Senior Vice President, Head of Vaccine Clinical Development
Dr. Kelly Lindert is the Senior Vice president of vaccines clinical development. She has 20 years of experience in pharma and biotech industries and spent nearly ten years working on vaccines, including pandemic vaccines, at Acambis and Novartis. At Novartis she rose to serve as Head of Development and led the team for the approval of Fluad and the first quadrivalent cell-based influenza vaccine in the US. More recently she worked at Moderna Therapeutics. She received her medical degree at the University of Chicago and trained in Urology at Stanford.
Rob Lopez, Facilities-Shipping & Receiving
Tim Luger, Research Associate II, RNA Process Development
Dr. Marquet is the co-Founder of ALMA Life Sciences, LLC, an early stage investment firm focusing on the creation and growth of innovative healthcare companies with an overall focus on prevention. She is also the co-Founder of AltheaDx, a commercial stage precision medicine company with the world’s leading pharmacogenomics test for anxiety and depression.
Dr. Marquet co-founded Althea Technologies in 1998 and led the company to the successful acquisition by Ajinomoto, a global Japanese company, leader in amino acid technology. During her tenure at Althea Technologies, Dr. Marquet had full P&L responsibility and built an organization with R&D and international commercial capabilities. Prior to starting Althea Technologies, Dr. Marquet held several positions in product development and pharmaceutical development in companies such as Vical and Amylin Pharmaceuticals.
She currently serves on the following Boards: Pfenex (PFNX) where she is a member of the Governance and Nomination Committee and Arcturus Therapeutics (ARCT) where is the Chairman of the Compensation Committee and a member of the Audit Committee. She also serves on the Board on several private companies such as Senté. As a former founder and CEO, Dr Marquet provides the Board with operational, fund raising expertise including venture, private equity and venture debt. She also brings expertise in M&A, global commercial development and regulatory strategies. She has a passion for building a winning culture of innovation and strategic growth.
She holds a Ph.D. in Biochemical Engineering from INSA/University of Toulouse, France. Dr. Marquet has received numerous prestigious awards throughout her career including the 2005 Regional Ernst & Young Entrepreneur of the Year award in the Life Sciences category, the Athena Pinnacle award, the Director of the Year award (Corporate Governance) from the Corporate Directors Forum and has been inducted into the CONNECT Entrepreneur Hall of Fame.
Suezanne Parker has 25+ years of pharmaceutical industry experience in preclinical drug development from research/discovery through global marketing approvals with several paradigms (gene therapy, small molecules, biologics) in multiple therapeutic areas (Vaccines, Infectious Disease, Neurology, Immunology, Oncology, Ophthalmology, Rare Disease). During her career she has lead Discovery Research, Pharmacology, Toxicology/Pathology, Toxicological Risk Assessment, PK/ADME, Bioanalytical, and Nonclinical Regulatory Submissions Writing Departments. She joined Arcturus Therapeutics as the VP of Translational Biology in August 2018 where she is responsible for the development of Arcturus’s novel RNA medicine platforms. Prior to Arcturus, she was the Senior Director of Toxicology at Shire where her team supported the nonclinical efforts for the marketing applications for Xiidra®, Vyvanse®, and Takhzyro®, for Dry Eye Disease, Binge Eating Disorder, and the first mAb approved for hereditary angioedema, respectively. She also provided nonclinical guidance for Shire’s first Gene Therapy (AAV) programs. Prior to joining Shire, Suezanne was at Biogen Idec Pharmaceuticals where she was the site head for Nonclinical Development (Toxicology, Bioanalytical, PK/DM, and the Animal Facility) at the San Diego Campus. As the Director of Preclinical Safety at Biogen Idec, she supported marketed products for MS (Avonex®, Tysabri®, and Fampridine®) as well as developmental candidates from research/discovery through Late Stage Development. While at Biogen Idec, Suezanne was the preclinical safety lead for Rituxan®, Tecfidera®, Plegridy®, and Zinbryta® for multiple sclerosis. Suezanne started her career in Industry at Vical Inc. in San Diego CA where she was responsible for the management of Pharmacology, Preclinical Safety and the Animal Facility. At Vical, she led the preclinical efforts for some of the first in human trials for plasmid DNA therapy. Suezanne completed her postdoctoral studies at Scripps Clinic and Research Foundation studying the viral pathogenesis of CNS disease. She received her PhD in Biochemistry and Molecular Biology from the University of California, Santa Barbara.
Deep Patel, Manager, CMC Operations
Joseph E. Payne, President & CEO, Director of the BoardBio
Joseph E. Payne, is the President and Chief Executive Officer of Arcturus Therapeutics. He serves on Arcturus’s Board since March 2013. He brings with him an exceptional track record of ushering novel therapeutics to the clinic including targeted RNA medicines utilizing lipid-mediated delivery technologies. Joseph’s background includes over 20 years of successful drug discovery experience at Merck Research Labs, DuPont Pharmaceuticals, Bristol-Myers Squibb, Kalypsys, and Nitto as evidenced by over 40 publications and patents, and several investigational new drug (IND) clinical candidates. His academic training includes a Bachelor's Degree in Chemistry, magna cum laude from Brigham Young University, a Master of Science in Synthetic Organic Chemistry from the University of Calgary and Executive Training Certification from MIT Sloan School of Management.
Yihua Pei, Scientist I, Formulation Development
Carlos Perez-Garcia, Senior Scientist, Translational Biology
Edgardo Pica, Research Associate I, Analytical Development
Linda Quirino, Senior Research Associate, Translational Biology
Huda Rabi, Research Associate I, Formulation Development
Kumar Rajappan, Principal Scientist, Chemistry
Tyler Raymer, Senior Manager, Facilities
River Recatto, Research Associate I, Formulation Development
Paloma Martinez Redondo, Scientist II, Translational Biology
Janet Reed, Executive Assistant
Pamela Resch, Executive Director, Quality and Regulatory Affairs
Josie Rivera, Research Associate I
Joseph Roberts, Assistant Controller
Scott Roberts, Director, CMC Operations and Supply Chain
Fred del Rosario, Senior Director, Information Technology
Sunil Raju, VP, Head of Drug Safety and PharmacovigilanceBio
Dr. Sunil Raju has over 12 years of industry experience across Drug Safety, Clinical Development and Medical Affairs in both large and small pharma. He is joining us from UroGen Pharma where he served as Vice President, Clinical Development and Pharmacovigilance. During his time there he was responsible for leading and building the Drug Safety department and played an instrumental role in the approval of their first product Jelmyto® for upper tract urothelial cancer (UTUC). He was also the Clinical Lead for their Phase 3 study of UGN-102 for non-muscle invasive bladder cancer (NMIBC). Previously, he spent 11 years at Pfizer where he worked across multiple roles initially in Medical Affairs (covering UK and Europe) and then transitioning to Drug Safety in the US where he held leadership roles in Worldwide Safety managing global teams across the US and China. In addition, he has experience of leading Drug Safety integrations of company acquisitions. Prior to joining industry, Sunil worked as a medical doctor in the UK specializing in Anesthesiology and Intensive Care having received his medical degree from Imperial College, London. He also holds a Bachelor of Sciences degree in Management from Imperial College.
Qian Ruan, Ph.D., is the Vice President of Technical Operations and Manufacturing of Arcturus Therapeutics. Dr. Ruan has extensive experience in bioprocess development from preclinical to licensure. Prior to Arcturus, Dr. Ruan worked at Emergent BioSolutions/PaxVax Inc. as Sr. Director of Process Development and Clinical Production. She has successfully built and led the team developed/manufactured/tech transferred oral delivery vectors and injectable virus-like particles for vaccines. She was the main contributor for multiple Investigational new drug (IND) and Biological Licensure Application (BLA) submissions. Her team supported AstraZeneca and Johnson & Johnson COVID-19 vaccine manufacturing at Emergent Bayview site to facilitate Emergency Use Authorization (EUA). Prior to Emergent BioSolutions/ PaxVax Inc, she worked for the Center of Cell and Gene Therapy at Baylor College of Medicine and developed early phase gene therapy drugs with adenovirus, herpes, and retrovirus platform technology. She published multiple articles and was the co-author of chapter “Purification of Adenovirus” in the book Adenoviral vectors for Gene Therapy. Qian holds a Ph.D. and a Bachelor's degree in Biochemical Engineering from South China University of Technology.
, Senior Vice President, Business Development & Alliance Management
Kevin Skol has nearly 20 years of experience in the pharmaceutical industry, primarily in corporate development, alliance management, strategy and licensing roles. He previously worked at RNA target-based companies Ionis Pharmaceuticals and Digital Gene Technologies and at specialty pharmaceutical companies Elan Corporation and Valeant Pharmaceuticals. At Ionis he led business development and licensing efforts that resulted in major pharmaceutical partnerships with Astra Zeneca, Roche, Janssen, Novartis and Biogen. The combined transaction value of collaborative agreements and partnerships which he led throughout his career is estimated at over $2 billion. Mr. Skol graduated with a B.A. from Yale University and has an MBA from Harvard Business School.
Claine Snow, Sr. IP & Transactions Counsel
Tyler Spencer, Senior Financial Analyst
Sean Sullivan, Executive Director, Process Development
Jocelyn Tabaldo, Administrative Assistant
Kiyoshi Tachikawa, Senior Research Fellow, Frontier Science
Wendy Taylor, Executive Director, Program Management
Phuong-Danh Tran, Research Associate I, Formulation Development
Ramon Diaz Trelles, Senior Scientist, Frontier Science
Jerel Vega, Senior Manager, CMC Operations
Andres Valderrama, Scientist II, Frontier Science
Dushyant Varshney, Executive Vice President & Chief Technology OfficerBio
, Executive Vice President & Chief Technology Officer
Dr. Varshney is a strategic executive leader with over 20 years of experience at global bio-pharma organizations where he successfully built and led clinical & commercial product development, manufacturing, technical operations, quality and CMC. Dr. Varshney has vast expertise in the entire product life-cycle of diverse biotech modalities including gene & cell-based therapy, biologics and vaccines. He has made significant contributions towards 20+ product launches, 70+ INDs, BLA, PAS submissions and ensured supply of 1B+ doses, $10B+ revenues at companies including Gilead, Pfizer, Novartis and Sanofi.
Most recently, Dr. Varshney was the Global Head of Manufacturing, Science & Technology at Kite-Gilead, where he built strong organization and rapid commercialization strategies for successful technology transfers, CMC filings, launch & patient access of Yescarta®, Tecartus®, viral vectors and clinical products. Prior to that, he served as the Vice President, Global Head of Technical Services, Operations & Supply at Jubilant, and as the Head of Manufacturing, Science & Technology at Pfizer, where he led multiple internal & external site teams in US, EU and Asia Pacific. At Novartis, he led and contributed to commercial technology transfer and site qualification for Flucelvax® (first US cell-based trivalent influenza vaccine), manufacturing of pre-pandemic vaccine stockpiles (bird & swine-flu) and pandemic response strategies.
Dushyant received his Ph.D. in Chemistry from University of Iowa, M.Pharm from Institute of Chemical Technology, Mumbai, and B.Pharm from University of Pune in India. He is a Stephen Covey Leadership Coach, Master Black-Belt in Operational Excellence, has published 40+ articles, book chapters and edited the book “Lyophilized Biologics & Vaccines” published by Springer.
Simone Ward, Life Sciences Patent Attorney
Rodrigo Yelin, Associate Director, Program Management
Howard Yu, Senior Scientist, Bioanalytical
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics is an industry leader in the application of RNA technologies for the treatment of disease and improved quality of life. The company’s aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. Backed by a management team with extensive experience in the discovery and development of RNA medicines, Arcturus is on the forefront of research and development of RNA chemistry and delivery technologies.
News & Events
March 4, 2013
Arcturus Therapeutics Begins Operations in Janssen Labs
Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency
Arcturus Therapeutics Announces Positive Interim ARCT-021 (LUNAR-COV19) Phase 1/2 Study Results for Both Single Shot and Prime-boost Regimens, and Up to $220 Million in Additional Financial Commitments from Singapore
Arcturus Therapeutics Announces Third Quarter 2020 Financial Results and Positive Clinical Updates for ARCT-810 Phase I Study and Additional ARCT-021 Interim Data
Arcturus Therapeutics Received Approval from Singapore Health Sciences Authority to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate and Provides New and Updated Clinical and Preclinical Data
